Skip to main content Accessibility help
×
Home

Can psychedelic compounds play a part in drug dependence therapy?

  • Ben Sessa (a1) and Matthew W. Johnson (a2)

Summary

After a 40-year hiatus there is now a revisiting of psychedelic drug therapy throughout psychiatry, with studies examining the drugs psilocybin, ketamine, ibogaine and ayahuasca in the treatment of drug dependence. Limitations to these therapies are both clinical and legal, but the possibility of improving outcomes for patients with substance dependency imposes an obligation to research this area.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Can psychedelic compounds play a part in drug dependence therapy?
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Can psychedelic compounds play a part in drug dependence therapy?
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Can psychedelic compounds play a part in drug dependence therapy?
      Available formats
      ×

Copyright

Corresponding author

Dr Ben Sessa, AddAction, 35 The Boulevard, Weston-Super-Mare BS23 1PE, UK. Email: bensessa@gmail.com

Footnotes

Hide All

Declaration of interest

None.

Footnotes

References

Hide All
1 James, W. The Varieties of Religious Experience: 263. Penguin Classics, 1983 (first edition 1902).
2 National Collaborating Centre for Mental Health. Alcohol-Use Disorders. Diagnosis, Assessment and Management of Harmful Drinking and Alcohol Dependence . NICE Clinical Guideline 115. British Psychological Society & Royal College of Psychiatrists, 2011.
3 Harkins, C, Morleo, M, Cook, PA. Evaluation of the Use of Alcohol Treatment Requirements and Alcohol Activity Requirements for Offenders in Cheshire (http://www.cph.org.uk/wp-content/uploads/2012/08/evaluation-of-the-use-of-alcohol-treatment-requirement-and-alcohol-activity-requirements-for-offenders-in-cheshire.pdf). Centre for Public Health & Cheshire Probation, 2011.
4 Miller, WR, Wilbourne, PL. Mesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders. Addiction 2002; 97: 265–77.
5 Home Office. The Government's Alcohol Strategy. Cm 8336. TSO (The Stationery Office), 2012.
6 Hickman, M, Carnwath, Z, Madden, P, Farrell, M, Rooney, C, Ashcroft, R, et al. Drug-related mortality and fatal overdose risk: pilot cohort study of heroin users recruited from specialist drug treatment sites in London. J Urban Health 2003; 80: 274–87.
7 Connock, M, Juarez-Garcia, A, Jowett, S, Frew, E, Liu, Z, Taylor, RJ, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007; 11: 1171.
8 World Health Organization Regional Office for Europe. The European Tobacco Control Report 2007. WHO, 2007.
9 Reus, VI, Smith, BJ. Multimodal techniques for smoking cessation: a review of their efficacy and utilisation and clinical practice guidelines. Int J Clin Pract 2008; 62: 1753–68.
10 Dyck, E. Psychedelic Psychiatry: LSD from Clinic to Campus. Johns Hopkins University Press, 2008.
11 Doblin, R. Dr Leary's Concord Prison experiment: a 34-year follow-up study. Psychoactive Drugs 1998; 30: 419–26.
12 Hendricks, PS, Clark, CB, Johnson, MW, Fontaine, KR, Cropsey, KL. Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision. J Psychopharmacol 2014; 28: 62–6.
13 MacLean, KA, Johnson, MW, Griffiths, RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol 2011; 25: 1453–61.
14 Halpern, JH. The use of hallucinogens in the treatment of addiction. Addiction Res 1996; 4: 177–89.
15 Bogenschutz, MP, Pommy, JM. Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses. Drug Test Anal 2012; 4: 543–55.
16 Krupitsky, EM, Grinenko, AY. Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. J Psychoactive Drugs 1997; 29: 165–83.
17 Sessa, B. Shaping the renaissance of psychedelic research. Lancet 2012; 380: 200–1.

Can psychedelic compounds play a part in drug dependence therapy?

  • Ben Sessa (a1) and Matthew W. Johnson (a2)

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.